Wegovi weight loss: the honest guide to semaglutide in the UK

You searched 'wegovi', here is what you were looking for

Most people who land on a page like this typed a quick search on their phone and got autocorrected, or simply went with the phonetic spelling. Either way, you are in the right place. The medicine you are asking about is Wegovy, manufactured by Novo Nordisk, and it contains semaglutide.

The reason this medicine gets so much attention is straightforward: for many people, it produces meaningful, sustained weight loss in a way that diet and exercise alone have not. That is not a marketing claim, it is what the clinical trial data consistently shows. If you have spent years trying to lose weight and feel quietly exhausted by the effort, that context matters and it is worth understanding what is actually happening biologically.

Semaglutide works by activating GLP-1 receptors, which are found in the gut, the pancreas and the brain. The result is a combination of reduced appetite, a slower rate of gastric emptying and a greater sense of fullness after smaller meals. Your body is not being tricked, it is responding to a signal it already uses, just amplified. The NHS medicine page for semaglutide covers the mechanism and common side effects in plain language and is worth reading alongside this page.

What the evidence says about how much weight people lose on Wegovy

The headline figure from STEP 1 is around 15% average body weight reduction over 68 weeks. That is a large study (adults with obesity or overweight plus at least one weight-related condition, no type 2 diabetes) and 15% is the average, meaning some participants lost more and some less. Weight loss was accompanied by improvements in blood pressure, waist circumference and quality-of-life measures.

Since then, Novo Nordisk has received MHRA approval for a higher maintenance dose. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg weekly pen, following earlier approval of the 7.2 mg dose itself in January 2026. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results. If you are comparing the two injectable options, our weight-loss injections overview sets them side by side.

These are trial results under controlled conditions. Results in everyday life vary depending on diet, activity, sleep, stress and other factors. A prescriber cannot promise a specific outcome, and any service that does should give you pause.

Who can be prescribed Wegovy in the UK, and the NHS versus private question

The licensed eligibility criteria are adults with a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Meeting the BMI number is the starting point, not the finishing line, a prescriber looks at your full health picture, including any medicines you already take.

On the NHS, Wegovy is available through specialist weight management services under NICE technology appraisal TA875, which sets additional conditions: use for a maximum of two years, within a multidisciplinary specialist service, for adults with a BMI of 35 or above and at least one comorbidity. Waiting lists are often long. NHS eligibility thresholds for tirzepatide (a different medicine, dispensed as Mounjaro) are being rolled out in phases through primary care, with different cohort criteria.

A private prescription route, through a regulated online pharmacy or clinic, follows the licensed SmPC criteria rather than the NHS commissioning thresholds. That is the route through services like nume: no waiting list, no referral required, subject to a prescriber confirming you are clinically suitable. For a broader look at what private weight-loss treatment involves, the weight-loss treatments overview is a reasonable starting point.

Side effects, safety and what to watch for

The most common side effects of Wegovy are gastrointestinal: nausea, constipation, diarrhoea, reflux and burping appear most often in the early weeks or after a dose increase, and they typically ease as your body adjusts. Staying well hydrated and eating smaller, lower-fat meals helps most people through the initial period.

Rarer but more serious effects include acute pancreatitis. Get urgent medical attention if you develop severe, persistent stomach pain that radiates to your back, with or without vomiting, the MHRA has issued specific guidance on this for GLP-1 medicines. Gallbladder problems, allergic reactions and symptoms of dehydration are also signals to act on promptly rather than wait out. You can report any suspected side effect through the MHRA's Yellow Card scheme.

Wegovy is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for anyone under 18. Women taking oral contraceptives should discuss contraception management with their prescriber, as semaglutide can affect absorption in some circumstances.

If you want to talk through whether Wegovy could be appropriate for your situation, starting a free consultation with our prescribers is the practical next step, and you can check what weight loss injections cost before you begin. The consultation is assessed the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated system.